BlossomHill Therapeutics (NASDAQ:BLSM) Reaches New 12-Month High – What’s Next?

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) hit a new 52-week high on Tuesday . The company traded as high as $23.38 and last traded at $22.40, with a volume of 13695 shares trading hands. The stock had previously closed at $21.74.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Zacks Research raised BlossomHill Therapeutics to a “hold” rating in a report on Wednesday, September 2nd. HC Wainwright began coverage on shares of BlossomHill Therapeutics in a report on Tuesday, September 1st. They issued a “buy” rating and a $35.00 target price on the stock. Lifesci Capital started coverage on shares of BlossomHill Therapeutics in a research report on Tuesday, September 1st. They issued an “outperform” rating and a $32.00 price target for the company. Guggenheim started coverage on shares of BlossomHill Therapeutics in a research note on Tuesday, September 1st. They set a “buy” rating and a $30.00 price target for the company. Finally, JPMorgan Chase & Co. began coverage on shares of BlossomHill Therapeutics in a research report on Tuesday, September 1st. They set an “overweight” rating and a $28.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $32.20.

BlossomHill Therapeutics Price Performance

Insider Transactions at BlossomHill Therapeutics

In other news, Director Bihua Chen acquired 312,500 shares of the company’s stock in a transaction on Monday, August 10th. The shares were bought at an average cost of $16.00 per share, with a total value of $5,000,000.00. Following the purchase, the director owned 3,614,034 shares of the company’s stock, valued at $57,824,544. This represents a 9.47% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Orbimed Advisors Llc acquired 625,000 shares of the business’s stock in a transaction on Monday, August 10th. The shares were purchased at an average price of $16.00 per share, with a total value of $10,000,000.00. Following the transaction, the director owned 2,714,279 shares in the company, valued at $43,428,464. The trade was a 29.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 1,573,900 shares of company stock worth $25,181,900 over the last quarter.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.